Evidence map›Paper›PMID 38041196›Full record

ReviewCancer cell international2023

Cancer stem cells and their niche in cancer progression and therapy.

Qiuping Liu, Zongliang Guo, Guoyin Li, Yunxia Zhang, Xiaomeng Liu, Bing Li, Jinping Wang, Xiaoyan Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. The relevance of mJournal of cancer research and clinical oncology · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. The role of stem cells in precision medicine: next-generation cancer treatment.Journal of the Egyptian National Cancer Institute · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qiuping LiuInstitute of Translational Medicine, College of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, 466001, Henan, China.
Zongliang GuoDepartment of General Surgery, Shanxi Province Cancer Hospital, Affiliated of Shanxi Medical University, Taiyuan, 030013, Shanxi, China.
Guoyin LiInstitute of Translational Medicine, College of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, 466001, Henan, China.
Yunxia ZhangInstitute of Translational Medicine, College of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, 466001, Henan, China.
Xiaomeng LiuInstitute of Translational Medicine, College of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, 466001, Henan, China.
Bing LiInstitute of Translational Medicine, College of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, 466001, Henan, China.
Jinping WangDepartment of Ultrasound, Shanxi Province People's Hospital, Taiyuan, 030012, Shanxi, China. jpwang06@126.com.
Xiaoyan LiDepartment of blood transfusion, Shanxi Provincial People's Hospital, Taiyuan, 030032, Shanxi, China. xiaoyanli5959@163.com.
Zhoukou Normal University · CNShanxi Medical University · CNShanxi Province Hospital of Traditional Chinese Medicine · CN

Funding

General Youth Project of Shanxi Natural Science Foundation 201901D211523Henan Science and Technology Research Plan Project of China 222102110412Natural Science Foundation of Henan Province 232300420283Scientific Research Start-up Foundation for Doctor of Zhoukou Normal University ZKNUC2020019
6 · The paper itself

Abstract

High recurrence and metastasis rates and poor prognoses are the major challenges of current cancer therapy. Mounting evidence suggests that cancer stem cells (CSCs) play an important role in cancer development, chemoradiotherapy resistance, recurrence, and metastasis. Therefore, targeted CSC therapy has become a new strategy for solving the problems of cancer metastasis and recurrence. Since the properties of CSCs are regulated by the specific tumour microenvironment, the so-called CSC niche, which targets crosstalk between CSCs and their niches, is vital in our pursuit of new therapeutic opportunities to prevent cancer from recurring. In this review, we aim to highlight the factors within the CSC niche that have important roles in regulating CSC properties, including the extracellular matrix (ECM), stromal cells (e.g., associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and mesenchymal stem cells (MSCs)), and physiological changes (e.g., inflammation, hypoxia, and angiogenesis). We also discuss recent progress regarding therapies targeting CSCs and their niche to elucidate developments of more effective therapeutic strategies to eliminate cancer.

Indexed as

cancer stem cellsCellular componentsCSC nicheExtracellular matrixTherapeutic strategies

Identifiers

PMID38041196
PMCPMC10693166
OpenAlexW4389221418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.